Company intelligence / Profile preview
Enlivex Therapeutics
Ness Ziona / Nes-Ziona / Ness-Ziona, Israelenlivex.com ↗
- Ownership
- Public · ENLV
- Development stage
- Phase 1
01
Overview
Enlivex has demonstrated a favorable safety profile for Allocetra™, with over 150 patients treated in clinical trials and no reported drug-related serious adverse events. Interim data from the Phase I stage of the moderate-to-severe knee osteoarthritis trial showed statistically significant improvements in efficacy endpoints without safety concerns. The ongoing randomized, placebo-controlled Phase II trial has completed enrollment and topline three-month data are expected by August 2025[2][6][7][9].
- Therapeutic areas
- Infectious DiseasesRheumatology
- Modalities
- Cell therapy (off-the-shelf)Macrophage reprogramming immunotherapy
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $17.5M
- Total revenue
- $0
- Enterprise value
- $12.3M
Beyond the preview
Go deeper on Enlivex Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enlivex Therapeutics.